论文部分内容阅读
【目的】评价应用赛尼哌(zenapax)作免疫抑制诱导治疗的疗效及安全性。【方法】2001年3月至2002年11月200例肾移植病人分为zenapax组(n=150)和对照组(n=50),前者采用zenapax作免疫抑制诱导治疗联合CsA／FK506+MMF+Pred三联维持治疗,后者除不用zenapax外,余同前。观察两组术后过敏反应、急性排斥、感染及白细胞减低等并发症。【结果】Zenapax组和对照组均无过敏反应发生,各有9例发生急性排斥反应(发生率为6％和18％),两组比较差异有统计学意义;两组感染发生率分别为8.7％和10％(P>0.05);两组分别有7例和4例术后白细胞减低。【结论】Zenapax可明显降低肾移植后早期急性排斥反应发生,而不增加感染、白细胞减低等并发症,是一种安全有效的免疫诱导药物;其远期疗效有待于进一步观察。
【Objective】 To evaluate the efficacy and safety of zenapax for immunosuppressive therapy. 【Methods】 200 cases of renal transplantation from March 2001 to November 2002 were divided into zenapax group (n = 150) and control group (n = 50). The former used zenapax as immunosuppressive therapy combined with CsA / FK506 + MMF + Pred triple therapy, the latter except zenapax, Yu Tong ago. Postoperative allergic reaction, acute rejection, infection and leukopenia were observed in two groups. 【Results】 There was no allergic reaction in the Zenapax group and the control group, with 9 cases of acute rejection (incidence rates 6% and 18%). The difference between the two groups was statistically significant. The incidence of infection in the two groups was 8.7 % And 10% respectively (P> 0.05). There were 7 and 4 postoperative leukopenia in the two groups respectively. 【Conclusion】 Zenapax can significantly reduce the incidence of early acute rejection after kidney transplantation without increasing the complications such as infection and leukopenia. It is a safe and effective immune induction drug. Its long-term efficacy needs further observation.